Project Grant R61MH143793
- Federal Grant Award Summary The National Institute of Mental Health awarded The Miriam Hospital a $705,322 Project Grant on September 16, 2025, under the Mental Health Research Grants program (CFDA 93.242) to develop and evaluate an artificial intelligence-based behavioral intervention for HIV prevention. The primary deliverable is CHIA (Chatbot for HIV Prevention and Action), a generative AI-powered chatbot tailored to deliver motivational interviewing techniques integrated with the...
- Federal Project Grant Award Summary Miresource, Inc. received a $627,600 project grant from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), awarded on September 12, 2025, with completion targeted for March 14, 2026. The project, conducted in partnership with the nonprofit Child Mind Institute (CMI), delivers an integrated digital mental health monitoring platform designed to improve longitudinal patient tracking and enable...
- Federal Grant Award Summary The Scintillon Institute received a $1,025,015 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, effective August 11, 2025, with completion targeted for July 31, 2027. The award funds development of a next-generation preclinical model of NeuroHIV that integrates neuro-immune-vascular system interactions to advance...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded the University of Alabama at Birmingham $250,000 under the Mental Health Research Grants program (CFDA 93.242) on August 18, 2025, for a multi-project research program focused on developing novel cell and gene therapy approaches for HIV cure. The award funds research extending through June 30, 2030, and involves a well-integrated collaboration among multiple principal investigators including Dr. Goepfert, Drs....
- Federal Project Grant Award Summary Icahn School of Medicine at Mount Sinai received a $3.61 million Project Grant from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), awarded on September 22, 2025, with a completion date of September 21, 2029. This four-year research initiative, titled "Targeting the NLRP3 Inflammasome to Mitigate Neuroinflammation and HIV Persistence in the CNS: Mechanisms and Therapeutic Strategies,"...
- Federal Project Grant Award Summary The National Institute of Mental Health (NIMH) awarded Child Mind Institute Inc. a $578,500 Mental Health Research Grants (CFDA 93.242) Project Grant effective May 1, 2025, through February 29, 2028. The award supports the development of integrated computational tools designed to link brain microstructure with functional dynamics in human and non-human primates. The project delivers three primary products: (1) an extension of the BrainBuilder tool to...
- Federal Project Grant Award Summary Spikegadgets, Inc. received a $1.27 million Project Grant from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), awarded August 1, 2025, with a completion date of July 31, 2028. The company is developing and commercializing an automated high-throughput neural recording platform designed to reduce inter-subject variability in neuroscience research while minimizing human labor requirements. The platform...
- Federal Grant Award Summary Translucence Biosystems, Inc. received a $375,000 Project Grant from the National Institute of Mental Health under the Mental Health Research Grants program (CFDA 93.242) awarded September 20, 2025, with completion targeted for May 31, 2027. The company is developing and refining a Vasculature Subtraction Parenchymal Quantification (VSPQ) workflow—an advanced software tool integrated into its proprietary 3D brain imaging and analysis platform. This specialized tool...
- Federal Grant Award Summary Rush University Medical Center received a $1.52M project grant from the National Institute of Mental Health under the Mental Health Research Grants program (CFDA 93.242), awarded April 1, 2026, with a completion date of March 31, 2028. The grant funds research utilizing a human-mouse chimera model to investigate the dynamics of HIV infection in the brain and its pathophysiological mechanisms. Specifically, the research examines how HIV-infected cells cross the...
- Federal Grant Award Summary Neuralthread Inc. received a $980,661 Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) on September 17, 2025, with a completion date of July 31, 2028. The company is developing TULLEKIT, a fully integrated deep brain neural recording system designed for stable, high-density electrophysiological recordings in freely moving non-human primates (NHPs). The system combines ultraflexible...
Modulo Bio, Inc. received a $1.48M project grant from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), awarded on March 1, 2026, with completion targeted for February 29, 2028. The awardee will develop an artificial intelligence (AI)-guided triculture platform to model HIV-associated brain injury (HABI) under antiretroviral therapy (ART) suppression. The platform integrates induced pluripotent stem cell (iPSC)-derived microglia, astrocytes, and neurons with morphological profiling and multi-omic data integration to classify microglial functional states and predict their impact on neuronal health. The research deliverables include: (1) development and validation of an HIV-infected, ART-suppressed triculture model utilizing machine learning-driven morphological profiling to identify HABI-specific microglial states; and (2) comprehensive characterization through neuroinflammatory profiling, behavioral analysis, and integration with publicly available patient datasets. Leveraging Modulo Bio's established triculture system previously validated in amyotrophic lateral sclerosis/frontotemporal dementia (ALS/FTD) research, this scalable platform addresses the critical gap in preclinical models that fail to recapitulate chronic suppressed infection and multicellular interactions characteristic of the modern treatment era for people with HIV.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.5m | 2/25/26 |